Jump to:
loading...| Preferred Name |
Daclizumab |
|
| Synonyms |
|
|
| ID |
http://scai.fraunhofer.de/MSOntology#Daclizumab |
|
| Context |
Drug : DBA000107 |
|
| isDefinedBy |
A recombinant monoclonal antibody interleukin-2 receptor antagonist. Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway. |
|
| prefixIRI |
MSOntology:Daclizumab |
|
| prefLabel |
Daclizumab |
|
| Reference | ||
| Synonym |
Roche brand of daclizumab C0663182 Hoffmann-La Roche brand of daclizumab Zenapax |
|
| subClassOf |
http://scai.fraunhofer.de/MSOntology#Disease_modifying_drugs |
Create mapping